Lantern Pharma (LTRN) stock is trading 5.3% down today at $3.38, continuing recent weakness. The decline comes despite the company's announcement on July 8, 2026, of the launch of ZetaOmics™, a new autonomous, intelligent “computational biologist” platform for cancer research. This also follows a 9.16% decline on July 7, 2026, and occurs amid a broader market pullback with major U.S. indices trading lower by 0.5–1%.